Another study similarly eliminated B-lineage cells in a mouse ovarian cancer model and showed that the synergistic anti-tumor effects of abemaciclib (CDK4/6 inhibitor) and anti-PD-1 therapy were lost in the absence of B cells [114]. Here, CDK4 is linked to neoplasm.